Medibio (ASX: MEB) (OTCQB: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through our Corporate Health product, we offer mental well-being solutions for businesses and we are developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. 

Medibio Highlights

  • Submission of FDA 510K application for MEBsleep
  • Completion of 4 commercial trials with global catering food services Compass PLC
  • Signed first annual licences agreement with PwC and Stantec
  • Depressive burden trial back underway after a pause due to COVID -19 lockdown
  • Restructured US operations as part of continuing cost reductions strategy

Shareholder Services

Investors may find additional information on Medibio stock, including real-time quotes, announcements, filings, and history, at the Australian Stock Exchange ( and OTC Markets ( The Medibio share registry is maintained by Computershare, where shareholders can access information about shareholding.


Investor Enquiries:

Medibio Investor Relations

Latest Investor Deck


Investor Inquiries

Contact Us

Corporate Webinar